69610-41-9

Basic information

• Product Name: N-BOC-L-Prolinal
• Synonyms: BOC-L-PROLINAL;N-BOC-L-PROLINAL;(S)-tert-Butyl 2-formylpyrrolidine-1-carboxylate;2-Formylpyrrolidine-1-carboxylic acid tert-butyl ester;(S)-N-Boc-pyrrolidine-2-carboxaldehyde, N-(tert-Butoxycarbonyl)-L-prolinal;(S)-N-BOC-Prolinal,97%;N-(Tert-butoxycarbonyl)-L-prol;(S)-1-Boc-2-forMylpyrrolidine
• CAS NO: 69610-41-9
• Molecular Formula: C₁₀H₁₇NO₃
• Molecular Weight: 199.25
• EINECS: 1592732-453-0
• Product Categories: Amino Aldehydes;Aldehydes;Amino Acid Derivatives;Building Blocks;C10-C12;Carbonyl Compounds;Chemical Biology;Chemical Synthesis;Organic Building Blocks;Peptide Chemistry;Heterocycles
• Mol File: 69610-41-9.mol
• Article Data: 178

Chemical Properties

• Boiling Point: 211 °C(lit.)
• Flash Point: 135 °F
• Appearance: clear light yellow viscous liquid
• Density: 1.063 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00483mmHg at 25°C
• Refractive Index: n20/D 1.462(lit.)
• Storage Temp.: Store at 0-5°C
• PKA: -3.03±0.40(Predicted)
• Water Solubility: Slightly soluble water. Soluble in chloroform.
• Sensitive: Air Sensitive
• CAS DataBase Reference: N-BOC-L-Prolinal(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-L-Prolinal(69610-41-9)
• EPA Substance Registry System: N-BOC-L-Prolinal(69610-41-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 1989
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 69610-41-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 69610-41-9 differently. You can refer to the following data:
1. Key building block for norsecurinine-type alkaloids and isaindigotidione carboskeleton.1,2
2. Key building block for norsecurinine-type alkaloids and isaindigotidione carboskeleton.

InChI:InChI=1/C10H17NO3/c1-10(2,3)14-9(13)11-6-4-5-8(11)7-12/h7-8H,4-6H2,1-3H3/t8-/m1/s1

Upstream product

• 79-37-8 oxalyl dichloride 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 67-68-5 dimethyl sulfoxide 
• 6216-63-3 N-Cbz-Prolinol 
• 201230-82-2 carbon monoxide 
• 73286-71-2 N-(tert-butoxycarbonyl)-2,3-dihydropyrrole 
• 135097-23-3 (2S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 115186-37-3 tert-butyl (2S)-2-{[N-methoxy(N-methyl)amino]carbonyl}pyrrolidine-1-carboxylate 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 2577-48-2 methyl (2S)-pyrrolidine carboxylate 
• 883565-15-9 C₁₅H₂₅NO₅ 
• 33305-75-8 L-proline ethyl ester monohydrochloride 

Downstream Products

• 133565-37-4 (4R,5S,2'S,3'R,2''S)-3-(3'-(N-tert-butoxycarbonyl-2''-pyrrolidinyl)-3'-hydroxy-2'-methylpropanoyl)-4-methyl-5-phenyl-2-oxazolidinone 
• 133645-51-9 (4R,5S,2'R,3'R,2S)-3-[3'-(N-tert-butoxycarbonyl-2-pyrrolidinyl)-3-hydroxy-2'-methylpropanoyl]-4-methyl-5-phenyl-2-oxazolidinone 
• 130832-50-7 (S)-2-[(R)-Hydroxy-(2-hydroxy-5-methoxy-phenyl)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 123172-77-0 (S)-2-[(S)-Hydroxy-(2-hydroxy-5-methoxy-phenyl)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 243983-11-1 (Z)-N-{[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]methylidene}benzylamine N-oxide 
• 130418-90-5 (S)-tert-butyl 2-ethynylpyrrolidine-1-carboxylate 
• 922529-39-3 ethyl 4-[2-[1-(tert-butoxycarbonyl)-(2S)-pyrrolidinyl]-(E)-ethenyl]benzoate 
• 1000397-28-3 tert-butyl (2S)-2-{[4-(4-bromo-3-chloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-ylamino]methyl}pyrrolidine-1-carboxylate 
• 260978-66-3 (2S)-[(4S,1E)-4-Benzyloxymethoxy-3-oxopent-enyl]-N-(tert-butoxycarbonyl)pyrrolidine 
• 176324-60-0 2-(R)-Vinyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester 
• 207915-21-7 (S)-2-((Z)-3-Benzyl-4-triisopropylsilanyloxy-but-1-enyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 207915-31-9 (S)-2-((E)-3-Benzyl-4-triisopropylsilanyloxy-but-1-enyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 198218-71-2 (S)-N-(tert-butoxycarbonyl)-2-(2-phenyl)ethenylpyrrolidine 
• 189823-25-4 (S)-2-{[Benzyloxycarbonyl-((S)-1-methoxycarbonyl-ethyl)-amino]-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Formal Fluorinative Ring Opening of 2-Benzoylpyrrolidines Utilizing [1,2]-Phospha-Brook Rearrangement for Synthesis of 2-Aryl-3-fluoropiperidines

A ring expansion of 2-benzoylpyrrolidines, which involves the formal fluorinative ring opening utilizing the [1,2]-phospha-Brook rearrangement under Br?nsted base catalysis and a subsequent intramolecular reductive amination, was developed. The operationally simple three-step protocol provides an efficient access to 2-aryl-3-fluoropiperidines. The methodology was further applied to the syntheses of azepanes and tetrahydroquinolines.

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT